Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· December 8, 2025

Rio2 Expands in Latin America With the Acquisition of the Producing Condestable Mine

View original at globenewswire.com
Rio2 Expands in Latin America With the Acquisition of the Producing Condestable Mine Positions Rio2 as a Diversified Latin American Gold Miner with Copper Exposure Concurrent C$140 Million Bought Deal Equity Financing to Support the Acquisition NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATI…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Condestable has 10+ years reserve life and demonstrates year-over-year reserve/resource growth

    80% confidence

  • Pro forma Rio2 will generate approximately US$330M in annual EBITDA

    80% confidence

  • Condestable mine will produce average annual EBITDA of approximately US$110M at consensus prices or US$145M at spot prices for 2026-2030

    80% confidence

  • Post-Fenix Phase 2 (2031+) total production potential is approximately 380,000 oz gold equivalent with gold contributing over 80% of revenue at long-term consensus prices

    80% confidence

  • Near-term production (2027-2028) will be approximately 180,000 oz gold equivalent with copper representing less than 30% of revenue at spot prices

    80% confidence

  • Copper is trading at historic lows relative to gold, making this an opportune time for copper acquisition

    80% confidence

  • Condestable is one of only two operating IOCG mines in Peru

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com